Page 1 - emap_newsletter_V2

eMAP – electronic EHA Medical HemAtology Program

Canadian Highlights from the European Hematology Association (EHA) 2022 Congress

TABLE OF CONTENTS The 27th Congress of the European Hematology Association
(EHA) was held from June 9-17, 2022, whereby leading experts
Select Abstracts on Cellular Therapy in B-cell Lymphoma gathered to discuss new and compelling data across the
spectrum of hematological diseases. As we are in a new era
LISOCABTAGENE MARALEUCEL (LISO-CEL) AS of managing hematological malignancies, this newsletter will
SECOND-LINE THERAPY FOR R/R LARGE B-CELL summarize results from key studies examining chimeric antigen
LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED receptor (CAR) T therapy to treat certain blood cancers, with
FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE expert commentary by leading Canadian hematologists on the
2 PILOT STUDY – Abstract S258 relevance to Canadian practice.

CLINICAL AND PATIENT-REPORTED OUTCOMES We invite you to interact with this newsletter through true or
IN A PHASE 3 STUDY OF AXICABTAGENE false questions to test your knowledge in the pre- and post-test,
CILOLEUCEL (AXI-CEL) VS. STANDARD-OF- listening to/viewing short clinical perspectives from our Scientific
CARE IN ELDERLY PATIENTS WITH RELAPSED/ Planning Committee, and visiting hyperlinks to various abstracts
REFRACTORY LARGE B-CELL LYMPHOMA of interest for further information.
(ZUMA-7) – Abstract S211
SCIENTIFIC PLANNING COMMITTEE
CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN
B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD John Kuruvilla, MD, FRCPC
STUDY FROM THE DESCAR-T REGISTRY – Abstract Chair, Scientific Advisory Board of Lymphoma Canada
S210 Associate Professor of Medicine, University of Toronto
Clinical Investigator, Division of Medical Oncology and
LONG-TERM SURVIVORS AFTER FAILURE OF Hematology, Princess Margaret Hospital
CAR-T CELL THERAPY FOR R/R LARGE B-CELL
LYMPHOMA (LBCL): A GLA/DRST STUDY – Abstract Donna E. Reece, BA, MD, FRCPC
P1448 Director, Program for Multiple Myeloma and Related Diseases,
University Health Network
Select Abstracts on Cellular Therapy in RRMM Professor of Medicine, University of Toronto
Clinician Investigator, Division of Medical Oncology and
RELAPSED/REFRACTORY MULTIPLE MYELOMA Hematology, Princess Margaret Cancer Centre
PATIENTS. A MULTICENTER RETROSPECTIVE
ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T The objectives of this newsletter are to:
CELL THERAPY – Abstract P902 • Review pivotal data presented at the EHA 2022 congress

CORRELATIVE ANALYSIS TO DEFINE PATIENT focused on novel cellular therapies (i.e., CAR T cell
PROFILES ASSOCIATED WITH MANUFACTURING approaches) in patients with B-cell lymphomas or relapsed/
AND CLINICAL ENDPOINTS IN RELAPSED/ refractory multiple myeloma (RRMM)
REFRACTORY MULTIPLE MYELOMA PATIENTS
TREATED WITH IDECABTAGENE VICLEUCEL • Examine the new data from a Canadian clinical perspective
(BB2121) – Abstract P866
• Assess current best practices and where/how to implement
CILTACABTAGENE AUTOLEUCEL, A BCMA- changes to optimize patient outcomes
DIRECTED CAR T CELL THERAPY, IN PATIENTS
WITH RELAPSED/REFRACTORY MULTIPLE PRE-TEST
MYELOMA: 2-YEAR POST LPI RESULTS FROM THE
PHASE 1B/2 CARTITUDE-1 STUDY – Abstract P961 Click here to quickly test your
knowledge on novel CAR T data
EFFICACY AND SAFETY OF ARI0002H, AN (TRUE or FALSE questions) before
ACADEMIC BCMA-DIRECTED CAR T CELL reviewing this newsletter summary
THERAPY WITH FRACTIONATED INITIAL THERAPY
AND BOOSTER DOSE IN PATIENTS WITH
RELAPSED/REFRACTORY MULTIPLE MYELOMA –
Abstract S103

ADDITIONAL ARTICLES OF INTEREST

Note that all abstract information was obtained from the EHA website http://www.ehaweb.org.